NEW YORK (GenomeWeb) – Rosetta Genomics today said that its PersonalizeDx business has signed a network participation agreement with MultiPlan, a cost management firm that runs preferred provider networks that serve more than 900,000 healthcare providers.
Rosetta's PersonalizeDx offers fluorescence in situ hybridization-based tests for prostate, bladder, and lung cancers, and has a CLIA lab in Lake Forest, California. It also performs PCR-based and immunohistochemical testing. Rosetta acquired PersonalizeDx two months ago for $2 million, 500,000 of Rosetta's ordinary shares, and certain undisclosed assets and services.
Last year, Rosetta signed a deal with MultiPlan to cover its molecular diagnostic tests including the Rosetta Cancer Origin Test.